GLONGHUI, May 23 | Cancer therapy developer Tango Therapeutics said the company will stop developing experimental cancer treatments due to liver toxicity in patients in early to mid-term trials. The treatment, called TNG348, is being tested alone and in combination with Lynparza (co-developed by AstraZeneca and Merck) in patients whose cancer expresses certain types of mutations. The company said serious liver abnormalities were observed in patients who continued the study for more than 8 weeks, adding that no patients had received a combination of TNG348 and Lynparza.
Tango Therapeutics停止开发某一癌症疗法
Tango Therapeutics stops developing a cancer treatment
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.